JP7627080B2 - Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物 - Google Patents

Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物 Download PDF

Info

Publication number
JP7627080B2
JP7627080B2 JP2021510693A JP2021510693A JP7627080B2 JP 7627080 B2 JP7627080 B2 JP 7627080B2 JP 2021510693 A JP2021510693 A JP 2021510693A JP 2021510693 A JP2021510693 A JP 2021510693A JP 7627080 B2 JP7627080 B2 JP 7627080B2
Authority
JP
Japan
Prior art keywords
cells
car
amino acid
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534784A (ja
JP2021534784A5 (https=
Inventor
ジョンソン，アダム
シー． ジェンセン，マイケル
Original Assignee
シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート filed Critical シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート
Publication of JP2021534784A publication Critical patent/JP2021534784A/ja
Publication of JP2021534784A5 publication Critical patent/JP2021534784A5/ja
Priority to JP2025009061A priority Critical patent/JP2025066785A/ja
Application granted granted Critical
Publication of JP7627080B2 publication Critical patent/JP7627080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021510693A 2018-08-31 2019-08-29 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物 Active JP7627080B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009061A JP2025066785A (ja) 2018-08-31 2025-01-22 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725599P 2018-08-31 2018-08-31
US62/725,599 2018-08-31
PCT/US2019/048814 WO2020047257A1 (en) 2018-08-31 2019-08-29 Methods and compositions comprising b7h3 chimeric antigen receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009061A Division JP2025066785A (ja) 2018-08-31 2025-01-22 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物

Publications (3)

Publication Number Publication Date
JP2021534784A JP2021534784A (ja) 2021-12-16
JP2021534784A5 JP2021534784A5 (https=) 2023-03-20
JP7627080B2 true JP7627080B2 (ja) 2025-02-05

Family

ID=69643750

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510693A Active JP7627080B2 (ja) 2018-08-31 2019-08-29 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物
JP2025009061A Pending JP2025066785A (ja) 2018-08-31 2025-01-22 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009061A Pending JP2025066785A (ja) 2018-08-31 2025-01-22 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物

Country Status (8)

Country Link
US (2) US12173071B2 (https=)
EP (1) EP3844191A4 (https=)
JP (2) JP7627080B2 (https=)
CN (1) CN113039206A (https=)
AU (1) AU2019333149A1 (https=)
CA (1) CA3110858A1 (https=)
IL (1) IL281129A (https=)
WO (1) WO2020047257A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4257154A4 (en) 2021-02-09 2026-04-22 Medilink Therapeutics Suzhou Co Ltd CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE
CN118647408A (zh) 2022-02-16 2024-09-13 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
CN119212733A (zh) 2022-05-18 2024-12-27 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
CN117986362A (zh) * 2022-11-04 2024-05-07 茂行制药(苏州)有限公司 靶向b7h3的通用型car-t细胞及其制备方法和应用
WO2024106941A1 (ko) * 2022-11-15 2024-05-23 주식회사 셀랩메드 B7-h3 키메라 항원 수용체 및 이의 용도
KR20260017010A (ko) * 2023-04-24 2026-02-04 엘피스 바이오파마슈티컬즈 장갑 항-b7h3 car-t 세포 및 암 치료에 있어서의 그 용도
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520994A (ja) 2010-03-04 2013-06-10 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
JP2015527070A (ja) 2012-08-20 2015-09-17 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための方法および組成物
WO2017044699A1 (en) 2015-09-10 2017-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 chimeric antigen receptors
JP2017515464A (ja) 2014-04-10 2017-06-15 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 細胞免疫療法のための方法および組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US10155038B2 (en) * 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9790282B2 (en) * 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
CN105873952A (zh) * 2013-10-31 2016-08-17 弗莱德哈钦森癌症研究中心 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
EP3288569A4 (en) * 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
US10188749B2 (en) * 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11771718B2 (en) * 2017-10-18 2023-10-03 Precigen, Inc. Polypeptide compositions comprising spacers
WO2020010239A1 (en) * 2018-07-06 2020-01-09 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptor polypeptides and methods of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520994A (ja) 2010-03-04 2013-06-10 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
JP2015527070A (ja) 2012-08-20 2015-09-17 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための方法および組成物
JP2017515464A (ja) 2014-04-10 2017-06-15 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 細胞免疫療法のための方法および組成物
WO2017044699A1 (en) 2015-09-10 2017-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 chimeric antigen receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Hematology & Oncology，2017年，Vol.10, No.1，Article number: 68, pp.1-11

Also Published As

Publication number Publication date
WO2020047257A1 (en) 2020-03-05
US20250136697A1 (en) 2025-05-01
IL281129A (en) 2021-04-29
CN113039206A (zh) 2021-06-25
EP3844191A1 (en) 2021-07-07
AU2019333149A1 (en) 2021-03-25
JP2025066785A (ja) 2025-04-23
CA3110858A1 (en) 2020-03-05
JP2021534784A (ja) 2021-12-16
EP3844191A4 (en) 2022-06-15
US20210324083A1 (en) 2021-10-21
US12173071B2 (en) 2024-12-24

Similar Documents

Publication Publication Date Title
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
JP7627080B2 (ja) Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物
JP7745616B2 (ja) 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体
CN111247242B (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
KR20190036551A (ko) Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
TW202122575A (zh) 工程化的ｔ細胞及其產生方法
EP4182336A1 (en) Chimeric molecules providing targeted costimulation for adoptive cell therapy
TWI840766B (zh) 改善免疫細胞功能
CN117858901A (zh) 制备表达嵌合抗原受体的细胞的方法
US20250249037A1 (en) Cd70 binding car-t cells comprising cd33 binding t-cell engaging antibody molecules
WO2022218402A1 (en) Fusion proteins and uses thereof
EP4323387A2 (en) Improved chimeric antigen receptors and uses thereof
HK40103403A (zh) 融合蛋白及其用途
HK40108858A (zh) 抗cll1抗体及其构建体
TW202216752A (zh) 用於過繼細胞療法之提供靶向共刺激之嵌合分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240909

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241224

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250122

R150 Certificate of patent or registration of utility model

Ref document number: 7627080

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150